Compounds, compositions and methods for cancer treatment

Patent metadata

Field	Value
Publication number	US-11142522-B2
Application number	US-201816480498-A
Country	US
Kind code	B2
Filing date	Feb 1, 2018
Priority date	Feb 3, 2017
Publication date	Oct 12, 2021
Grant date	Oct 12, 2021

Abstract

The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.

First claim

What is claimed is:

1. A compound having the structure:

or a pharmaceutically acceptable salt, or prodrug thereof.

2. A pharmaceutical composition containing a compound of claim 1 or a pharmaceutically acceptable salt, or prodrug thereof, and one or more pharmaceutically acceptable carriers or excipients.

3. A method of killing or reducing the survival of a cancer cell selected as responsive to a phosphodiesterase 3A (PDE3A) and/or (PDE3B) modulator involving contacting the cell with a compound of claim 1 where the cell was selected as having an increase in the level of a PDE3A and/or PDE3B or Schlafen 12 (SLFN12) polypeptide or polynucleotide, or combination thereof, relative to a reference, thereby reducing the survival of the cancer cell.

4. A method of reducing cancer cell proliferation in a subject pre-selected as having a cancer that is responsive to one or more PDE3A and/or PDE3B modulators comprising administering to the subject a compound of claim 1 , where the subject is pre-selected by detecting an increase in the level of a PDE3A and/or PDE3B and Schlafen 12 (SLFN12) polypeptide or polynucleotide, or combination thereof, in a cell from the subject's cancer relative to a reference, thereby reducing cancer cell proliferation in said subject.

5. A method for treating a hyperproliferative disease responsive to a PDE3A and/or PDE3B modulator in a subject in need thereof comprising administering a compound of claim 1 ; or a pharmaceutically acceptable salt, or prodrug thereof to the subject.

6. The method according to claim 5 where the hyperproliferative disease is cancer.

7. The method according to claim 6 wherein said cancer is a bone, breast, cervical, colon, endometrium, gastrointestinal stromal tumor (GIST), head and neck, hematopoietic, kidney, leiomyosarcoma, liver, lung, lymphoid, melanoma, ovarian, pancreas, prostate, soft-tissue sarcoma, thyroid cancer, or urinary tract cancer.

8. The composition according to claim 2 wherein the compound is

9. The method of claim 3 , further comprising detecting a lack of decrease in the level of expression of CREB3L1 polypeptide or polynucleotide relative to a reference and/or a decrease in the level of SLFN12.

10. The method according to claim 3 , wherein the compound is

11. A kit for decreasing cancer cell proliferation in a subject pre-selected as having a cancer that is responsive to a PDE3A/PDE3B modulator containing one of the compounds of claim 1 ;
or a pharmaceutically acceptable salt, or prodrug thereof.

12. A method for the manufacture of a pharmaceutical composition for the treatment of cancer responsive to a PDE3A and/or PDE3B modulator, comprising mixing a PDE3A and/or PDE3B modulator with one or more pharmaceutically acceptable excipients,
where the PDE3A and/or PDE3B modulator is a compound of claim 1 ;
or a pharmaceutically acceptable salt, or prodrug thereof.

13. The method of claim 12 , wherein the cancer is a bone, breast, cervical, colon, endometrium, gastrointestinal stromal tumor (GIST), head and neck, hematopoietic, kidney, leiomyosarcoma, liver, lung, lymphoid, skin, melanoma, ovarian, pancreas, prostate, soft-tissue sarcoma, thyroid cancer, or urinary tract cancer.

14. The method of claim 13 , wherein the cancer is melanoma or cervical cancer.

15. A method of preparing compound 1 , said method comprising the steps of
reacting a compound of formula (IV)

with pure morpholine at elevated temperatures, or with morpholine and a base, optionally in a polar aprotic solvent, at reflux temperature, to obtain Compound (V)

which then is reacted with a strong base, in a polar aprotic solvent at low temperatures followed by addition of (C 1 -C 4 -alkyl)bromoacetate or (C 1 -C 4 -alkyl)chloroacetate neat or in a polar aprotic solvent,
allowing the mixture to warm up from initial −78° C. to RT, optionally isolating the crude product, and then adding either hydrazine or hydrazine hydrate in a polar protic organic solvent under reflux temperature to obtain the racemic compound 1c

and subsequently performing a separation of enantiomers of Compound 1c to obtain Compound 1 and Compound (1a)

whereby optionally compound (1a) is converted into the racemic compound (1c) which could then be separated again in order to obtain Compound 1 and less of the initial amount of compound 1a isolated from the enantiomeric separation.

16. A method for the preparation of Compound 1 whereby compound (IV)

is reacted with strong base in a polar aprotic solvent at low temperatures −78° to −60° C., followed by addition of (C 1 -C 4 -alkyl)bromoacetate or (C 1 -C 4 -alkyl)chloroacetate neat or in a polar aprotic solvent allowing the mixture to warm up from initial −78° C. to RT, optionally isolating the crude product, and then adding either hydrazine or hydrazine hydrate in a polar protic organic solvent under reflux temperature to produce compound (VII)

and further allowing compound (VII) to react with pure morpholine at elevated temperatures, or with morpholine and a base in a polar aprotic solvent at reflux temperature to obtain Compound 1c

and subsequently performing a separation of enantiomers of Compound 1c to obtain Compound 1 and Compound (1a)

whereby optionally compound 1a is converted into racemic material which could then be separated in order to obtain Compound 1 and less of the initial amount of compound 1a.

Assignees

• Broad Inst Inc
• Dana Farber Cancer Inst Inc
• Bayer Ag
• Bayer Pharma AG

Inventors

• Lewis Timothy A
• Wu Xiaoyun
• Greulich Heidi
• Meyerson Matthew
• Ellermann Manuel
• Lienau Philip
• Eis Knut
• Wengner Antje Margret
• Kopitz Charlotte Christine
• Lange Martin

Classifications

• C07D413/10 Primary

  linked by a carbon chain containing aromatic rings · CPC title

• A61K31/501 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07D237/04

  having less than three double bonds between ring members or between ring members and non-ring members · CPC title